1328P - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial
| Autor: | Reijers, I.L.M. 1, Rozeman, E.A. 1, Menzies, A.M. 2, Versluis, J.M. 1, van de Wiel, B.A. 3, Sikorska, K. 4, Eriksson, H. 5, Shannon, K. 6, Bierman, C. 3, van Tinteren, H. 4, Gonzalez, M. 2, Spillane, A.J. 6, Saw, R.P. 6, Scolyer, R.A. 7, van Akkooi, A.C.J. 8, Hansson, J. 5, Long, G.V. 9, Blank, C.U. 1 |
|---|---|
| Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v541-v541 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|